期刊
CANCER
卷 120, 期 11, 页码 1620-1629出版社
WILEY
DOI: 10.1002/cncr.28594
关键词
androgen deprivation therapy; prostate cancer; radiotherapy; gonadotrophin-releasing hormone antagonist; luteinizing hormone-releasing hormone agonist
类别
资金
- Ferring Pharmaceuticals
Androgen deprivation therapy (ADT) is now a well-established standard of care in combination with definitive radiotherapy for patients with unfavorable intermediate-risk to high-risk locally advanced prostate cancer. It is also well established that combination modality treatment with ADT and radiotherapy is superior to either of these modalities alone for the treatment of patients with high-risk locally advanced disease. Current treatment guidelines for prostate cancer in the United States are based on the estimated risk of recurrence and death. This review examines the clinical evidence underpinning the use of ADT and radiotherapy among patients with high-risk localized and locally advanced disease in the United States. This review also considers the rationale for moving from traditional luteinizing hormone-releasing hormone agonists to more recently developed gonadotrophin-releasing hormone antagonists. Cancer 2014;120:1620-1629. (c) 2014 American Cancer Society. This review examines the clinical evidence underpinning the use of androgen deprivation therapy and radiotherapy for patients with high-risk localized and locally advanced prostate cancer in the United States. It also considers the rationale for moving from traditional luteinizing hormone-releasing hormone agonists to more recently developed gonadotrophin-releasing hormone antagonists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据